FGEN

FibroGen

No price yet

Announcements

Nothing here yet

Daily updates

Nothing here yet

FDA designations

Nothing here yet

News

FibroGen initiates Phase 2 monotherapy trial of FG-3246, a first-in-class CD46 targeting ADC, in metastatic castration-resistant prostate cancerSep 24, 2025
FibroGen announces approval of sale of FibroGen China to AstraZeneca by China State Administration for Market RegulationAug 18, 2025
FibroGen announces positive Type C meeting with FDA for Roxadustat in anemia patients with lower-risk myelodysplastic syndromesAug 7, 2025